PRELIMINARY INVESTIGATION ON EFFECTS OF BURANTASHI EXTRACT ON LIPOPROTEINS OF ALBINO MALE AND FEMALE WHISTAR RATS
This work was carried out to investigate the effects of Burrantashi extracts on the lipoproteins Burantashi is a popular seasoning agent to barbecued meat (Suya) in Nigeria. Found in the northern parts of the country. Lipoproteins are the principal steroid or fat that is synthesized in the liver or intestines of animals. Erectile dysfunction (ED) is defined as the consistent or recurrent inability of a man to attain or maintain penile erection, sufficient for sexual activity (2nd international consultation on sexual dysfunction Paris, June 28th –July 1st 2003). Following the discovery and introduction of burantashi research on the mechanism underlying penile erection, had an enormous boost and many preclinical and clinical papers have been published in the last five years on the peripheral regulation of, and the mediators involved in human penile erection. The most widely accepted risk factors for e.g. are discussed. The research is focused on human data and the safety and effectiveness of burantashi stem as a phosphodiesterase – 5- inhibitors (PDEs) used to treat erectile dysfunction.
Erectile dysfunction, ED, is a sexual dysfunction that affects the reproductive systems of both men and women. By definition according to National Institute of Health consensus Development Panel on impotence (1993), in Males, it is a sexual dysfunction characterized with the inability to develop or maintain an erection of the penis sufficient for satisfactory sexual performance. It is also known as Male impotence or Baby D syndrome, while in women, according to American Psychiatric Association (1994), it is characterized with the persistent or recurrent inability to attain, or maintain until completion of the sexual activity, an adequate Lubrication- Swelling response that otherwise is present during female sexual arousal and sexual activity is thus prevented. Hence, it is called Women impotence or female erectile dysfunction. The word impotence may also be used to describe other problems that may interfere with sexual intercourse and reproduction, such as lack of Sexual Desire and problems with ejaculation or orgasm. Using the term “erectile dysfunction,” however makes it clear that those other problems are not involved (NIH, 2005).
An erection occurs as a hydraulic effect due to blood entering and being retained in sponge-like bodies within the penis and clitoris. The process is most often than not initiated as a result of sexual arousal, when signals are transmitted from the brain to nerves in the pelvis. Erectile dysfunction is, therefore indicated when an erection is consistently difficult or impossible to produce, despite arousal (Laumann et al., 1999).
1.1 PREVALENCE OF ERECTILE DYSFUNCTION IN WOMEN
Erectile dysfunction which is known as Female erection dysfunction in women occurs in about 43% of American Women (NIH Consensus Conference, 1993). And this medical Condition is a persistent or recurrent inability to attain or maintain clitoral erection until completion of the sexual activity, an adequate Lubrication –Swelling response that is normally present during Female sexual arousal and sexual activity is therefore, absent. The individual having the condition is said to experience frigidity (American Psychiatric Association, 1994). Again, According to Otubu et al. (1998) about 8.7% of Women suffer from this very condition in the United States while between 35.3 – 40%, according to Adequnloye (2002) and Eze (1994) of Women in Nigeria suffer from this condition. Spector and Carey (1994) reported 5-10% in the United States. In addition, Female erectile dysfunction occurs at any age but majorly in old age. Hence, the most significant age related change is menopause (Karen, 2000) and (Rod et al., 2005).
However, erectile dysfunction may be caused by diabetes, atherosclerosis, hormonal imbalances, neurological problems etc. (Organic causes) or stress, depression etc. Because treating the underlying causes (Organic or Psychological), the first line treatment of ED consists of a trial of PDES inhibitor (the first of which was Sildenafil or Viagra). In some cases, treatment can involve prostag-Landin tablets in the Urethra, intravenous injection with a fine needle into the penis or clitoris that causes swelling of Penis or Clitoris Pump or Vascular surgery, estrogen replacement therapy for the women etc.
Although there are various methods and techniques that are used to treat this very condition, however, for the purpose of this project, the treatment is restricted to Yohimbe, an extract from Pausinystalia yohimbe.
PRELIMINARY INVESTIGATION ON EFFECTS OF BURANTASHI EXTRACT ON LIPOPROTEINS OF ALBINO MALE AND FEMALE WHISTAR RATS
1.2 PREVALENCE OF ERECTILE DYSFUNCTION IN MEN
Erectile dysfunction, ED, varies in severity; some men have a total inability to achieve an erection, others have inconsistent ability to achieve an erection, and still others can sustain only brief erection. The variation in severity of erectile dysfunction makes estimating its frequency difficult.
Many men also are reluctant to discuss erectile dysfunction with their doctors, and thus, the condition is under-diagnosed. Nevertheless, experts have estimated that ED affects 30 million men in the United States. Again, according to the statistical research carried out by Adegunloye (2002) and Eze (1994) respectively in Nigeria, results shows that about 23-26.4% of men suffer from this condition while according to Spector and Carey (1999) discovered that about 4-9% of men suffer from the condition in the United States.
While erectile dysfunction can occur at any age, it is uncommon among young men and more common in the elderly. By the age of 45, most men have experienced erectile dysfunction at least some of the time. According to the Massachusetts Male Aging Study, complete impotence increases from 5% among Men 40 years of age to 15% among Men 70 years and older. Population studies conducted in the Netherlands found out that some degree of ED occurred in 20% of Men between 50 – 54 and in 50% of men between ages 70 – 78. In 1998, the National Ambulatory Medical care Survey counted 1,520,000 Doctor Offices visited for ED.
1.3 OBJECTIVE STUDY AND AIMS
1.4 NITRIC OXIDE-CYCLIC GMP PATHWAY WITH SOME EMPHASIS ON CAVERNOSAL CONTRACTILITY
Nitric Oxide (NO) is formed from the conversion of L- arginine by nitric oxide synthase (NOS), endothelial (eNOS), and inducible (iNOS). nNOS is expressed in penile neurons innervating the corpus Cavernosum, and eNOS protein expression has been identified primarily in both Cavernosal Smooth Muscle and endothelium. NO is released from nerve endings and endothelial cells and stimulates the activity of soluble guanylate cyclase (sGC), leading to an increase in cyclic guanosine- 3‟,5‟,- Monophosphate (cGMP) and, finally, to Calcuim depletion from the cytosolic space and Cavernous Smooth muscle relaxation. The effect of cGMP are mediated by cGMP dependent Protein Kinase, cGMP-gated ion channels, and cGMP-regulated Phosphodiesterases (PDE). Thus, cGMP effect depends on the expression of a Cell-Specific cGMP-receptor protein in a given cell type.
Numerous systemic vasculature diseases that cause erectile dysfunction (ED) are highly associated with endothelial dysfunction, which has been shown to contribute to decrease erectile function in men and a number of animal models of penile erection. Based on the increasing knowledge of intracellular signal propagation in cavernous smooth muscle tone regulation, selective PDE inhibitors have recently been introduced in the treatment of ED. Phosphodiesterase-5 (PDE5) inactivates cGMP, which terminates NO-cGMP-mediated SMooth Muscle relaxation. Inhibition of PDE5 is expected to enhance penile erection by preventing cGMP degradation. Development of pharmacologic agents with this effect has closely paralleled the emerging science.
﴾International Journal of impotence Research (2004)﴿. Nitric oxide (NO) was first described by Stuehr and Marletta (1985) as a product of activated murine machrophages. Also, the substance known as endothelium- derived relaxing factor (EDRF), described by Furchgott and Zawadzki (1980), has been identified as NO.
Soluble guanylate cyclase (sGC), responsible for the enzymatic conversion of guanosine -5- triphosphate (GTP) to cyclic guanosine -3‟5‟- monophosphate (cGMP), was first identified as a constituent of mammalian cells almost three decades ago. No and cGMP together comprise an especially wide-ranging signals transduction system when one considers the many roles of cGMP in physiological regulation, including smooth muscle relaxation, visual transduction, intestinal ion transport, and platelet function.
Erectile dysfunction (ED) is defined as the constituent inability to achieve or maintain an erection sufficient for satisfactory sexual performance and is considered to be a natural process of ageing. Studies have shown that ED is caused by inadequate relaxing of the corpus cavernosum with defeat in NO production.
It is clear that NO is the predominant neurotransmitter responsible for cavernasal Smooth muscle relaxation and hence penile erection. Its action is medicated through the generation of the second messenger cGMP. Neutrally, derived NO has been established as a mediator of smooth muscle relaxation in the penis and it is thought that constitutive forms of nitric oxide synthase (NOS) work to mediate the convesion of GTP to the intracellular second messenger cGMP in smooth muscle cells. An increase in cGMP modulates cellular events, such as relaxation of smooth muscle cells.
This review will describe current knowledge of cellular events involved in cavernosal relaxation and the range of putative factors involved in NO-mediated relaxation.
1.5 SYNTHESIS OF Nitric Oxide (NO).
Recent observation suggest that the main site of NO biosythesis in human corpus cavernosum is within the terminal branches of cavernosal nerves supplying the erectile tissue. It is strongly suggested that NO released from nonadrenergic – noncholinergic (NANC) neurons increases the production of cGMP, which in turn relaxes the cavernous smooth muscle. Endothelial –derived NO plays a major role in the penis. Some suggest that NO is highly labile, therefore it cannot be stored as a preformed neurotransmitter. Other proerectile mediators, such as acetylcholine, calci-tonin gene related peptide (CGRP) or substance P, act via endothelialcells by prompting the synthesis and release of NO by these cells, ﴾Bivalacqua et al., 2001). Found in their study that in vivo adenoviral gene transfer of CGRP in combination with adrenomedullin (ADM) or prostaglandin E1(PGEI) induce penile erection by activating different receptors.
The combination of molecular oxygen and the amino acid arginine in the presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and NO synthase, (NOS) yields citruline nitrogen of L- arginine. L- citrulline can be converted by arginine synthase (AS) to form L-arginine, the precursor for NO. Each of these enzymes, co-factors, or transport systems could be an eventual target of pharmacologic intervention in the NO cascade. Oral administration of L-arginine in high doses seems to cause significant subjective improvement in sexual function in men with Organic ED only if they have decreased production of plasma and urine nitrite and nitrates, which are stable metabolites of NO. There are at least three isoform of NOS (neuronal, endothelial, and macrophage). A constitutive form of NOS is found in endothelial and neurons, and is calcium dependent. The constitutive NOS-3, whereas the constitute NOS found in neutral and epithelial tissue has been named NOS-1. An inducible form of NOS, now designated iNOS, is calcium independent. It is induced within 4-24h of the appropriate stimulus and can produce NO in a 100-fold greater amount than can constitutive NOS.
Neutral NOS has multiple regulator sites, including binding sites for nicotinamide adenine dinucleotide phosphate (NADPH), Flavin adenine dinucleotide (FAD), and flavin Monoucleotide (FMN). All of these are (O factors for the synthesis of NO. these cofactors bind to a reductase domain to process election transfer. This is then linked to heme and tetrahydrobiopterin (BH4) – containing catalytic oxygenenase domain by calcium-calmodulin complex (figure 2).
The complete enzyme converts L-arginine to L- citrulline and NO in the presence of molecular Oxygen. In addition to the various protein modules or domains of neuronal NOS, which are involved in electron transfer, substrate binding, oxygen activation and calcium binding, a four amino –acid motif (glycine- Leucine-glycine- Phenylalanine, GLGF) has been identified in amino terminal region of NOS-1. Although the function of this amino-acid motif in NOS-2 has not been established, a study on other proteins containing this motif indicates that it may serve to target proteins to specific sites in the cell. nNOS has a recognition site for calmodulin that is also present in eNOS and macrophages NOS. The constitutive isoforms are generally regulated by Ca2+ -calmodulin, whereas inducible forms are not.
nNOS in the penis is expressed primarily as a variant of the brain form of nNOS and has been termed PnNOS. It has an additional 102-bp alternative exon located between exons 16 and 17. The function of this additional coding region is unknown. PnNOS is thought to be responsible for trigging the nitregic mechanism responsible for cavernosal relaxation. A similar variant, nNO-SU is present in the neuromuscular plates of skeletal muscles, including the perineal muscles involved in erectile rigidity and ejaculation in rats. The control of NO synthesis in the Cavernosal nerve, whether due to sexual stimulation emanating. Centrally, from the brain, or peripherally by means of the dorsal nerve spinal reflex is assumed to be exerted through the activation of PnNOS activity. This mechanism occurs mainly by Ca2+ binding to calmodulin by means of Ca2+ flux through the N-methyl-D-aspartate receptor (NMDAR). Both the NMDAR and inhibitors of nNOS activity, such as protein inhibitors of nNOS activity, such as protein inhibitors of NOS(PIN) and carboxy terminal POZ Ligand of nNOS (CAPON), also bind to nNOS .
The nitrognic activation of penile erection is not restricted to peripheral nerves of the corpora cavernosa but is also dependent on central nervous system (CNS) regulated. It was found that PnNOS, the brain type nNOS, and PIN were expressed in the hypothalamus in contrast, NMDAR1-T was expressed only in the penis, whereas the brain –type- NMDARI was present in the brain and sacral spinal cord and not in the Penis. PnNOS was found in the media preoptic area, posterior magnocellular, and the Parvocellular regions of paraventriccular nucleus, Supraoptic nucleus, septohypothalamic nucleus, medial septum, Cortex, and in some of the nNOS staining neurone through the brain. It was absent in organum vasculosum of the lamina terminalis. PIN staining was present in neurons of the medial septum and cortex, but not in the supraoptic nucleus septohypothalamic nucleus or organum vasculosym of the Laminal terminals.
Inhibitors of NOS are substrate analogues of L-arginine, such as N-Monomethyl -L- arginine (L- NMMA), nitro-L- arginine methyl ester (L-NAME). and N-amino –L- arginine.Drugs that inhibit the dephosphorylation of eNOS might alleviate ED. eNOS abnormalities may play a role in diabetic ED. Hyperglycemia decreases NO production by eNOS via O-Linked glycossylation of eNOS at the targets S1177 in hyperglycemic cell culture conditions and in animal models of diabetes. ED in diabetes is associated with peripheral nerve damage but may involve diminished endothelial-production of NO as well. Numerous systemic vasculature, diseases (hypertension, atherosclerosis, hyperoholesterolemia, diabetes mellitus, etc) that cause ED are highly associated with endothelial dysfunction, which has been shown to contribute to decreased erectile function in men and a number of animal models of penile erection.
The activity of nNOS is controlled by a number of mechanisms.
A balance of various inhibitory and stimulatory transcription factors determines gene transcription of the enzyme. Enzyme activity can be halted by phosphorylation by a cyclic adenosine Monophosphate (cAMP) – dependent protein kinase (PKA) or cGMP- dependent protein kinase (PKG), providing a negative feed back loop. The enzyme is activated by increased intracellular calcium, which binds to calmodulin to form the essential cofactor. It is also likely that co- transmitters influence nNOS activity perhaps by altering calcium concentration by activation of prejunctional receptors. VIP
is a probable stimulatory co-transmitter, while noradrenaline acting on x-2 adrenoceptors inhibits NO formation.